JP2005516901A - １Ｈ−ピロロ［３，２−ｂ］ピリジン−３−カルボン酸アミド化合物 - Google Patents
１Ｈ−ピロロ［３，２−ｂ］ピリジン−３−カルボン酸アミド化合物 Download PDFInfo
- Publication number
- JP2005516901A JP2005516901A JP2003545655A JP2003545655A JP2005516901A JP 2005516901 A JP2005516901 A JP 2005516901A JP 2003545655 A JP2003545655 A JP 2003545655A JP 2003545655 A JP2003545655 A JP 2003545655A JP 2005516901 A JP2005516901 A JP 2005516901A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- pyrrolo
- pyridine
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 1H-pyrrolo [3,2-b] pyridine-3-carboxylic acid amide compound Chemical class 0.000 title claims description 214
- 150000001875 compounds Chemical class 0.000 claims abstract description 251
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 92
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 91
- 238000000338 in vitro Methods 0.000 claims abstract description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 137
- 150000002367 halogens Chemical class 0.000 claims description 136
- 229910052739 hydrogen Inorganic materials 0.000 claims description 119
- 239000001257 hydrogen Substances 0.000 claims description 119
- 150000003839 salts Chemical class 0.000 claims description 92
- 102000005962 receptors Human genes 0.000 claims description 87
- 108020003175 receptors Proteins 0.000 claims description 87
- 150000002431 hydrogen Chemical class 0.000 claims description 73
- 125000000217 alkyl group Chemical group 0.000 claims description 69
- 125000006413 ring segment Chemical group 0.000 claims description 59
- 125000004432 carbon atom Chemical group C* 0.000 claims description 52
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 48
- 125000003545 alkoxy group Chemical group 0.000 claims description 45
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 45
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 44
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 44
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 44
- 125000003282 alkyl amino group Chemical group 0.000 claims description 42
- 125000004043 oxo group Chemical group O=* 0.000 claims description 42
- 125000001424 substituent group Chemical group 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 41
- 229910052799 carbon Inorganic materials 0.000 claims description 38
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 34
- 125000003118 aryl group Chemical group 0.000 claims description 34
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 33
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 28
- 125000004076 pyridyl group Chemical group 0.000 claims description 26
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 22
- 125000004193 piperazinyl group Chemical group 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 19
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 18
- 239000001301 oxygen Substances 0.000 claims description 18
- 229920006395 saturated elastomer Polymers 0.000 claims description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 16
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 14
- 208000019901 Anxiety disease Diseases 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 230000036506 anxiety Effects 0.000 claims description 11
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 11
- 238000004458 analytical method Methods 0.000 claims description 10
- 208000019116 sleep disease Diseases 0.000 claims description 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 9
- 125000002971 oxazolyl group Chemical group 0.000 claims description 9
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 9
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 125000002883 imidazolyl group Chemical group 0.000 claims description 8
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 7
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims description 7
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 7
- 125000001041 indolyl group Chemical group 0.000 claims description 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 7
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 7
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 7
- 230000007781 signaling event Effects 0.000 claims description 7
- 125000001425 triazolyl group Chemical group 0.000 claims description 7
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 6
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 claims description 6
- 150000001721 carbon Chemical group 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 6
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 5
- VFTNLQWTHUFIBV-UHFFFAOYSA-N 5-(1-methylpiperidin-4-yl)oxy-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC=C(NC=C2C(=O)NC=3N=CC=CC=3)C2=N1 VFTNLQWTHUFIBV-UHFFFAOYSA-N 0.000 claims description 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 5
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 5
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 5
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims description 5
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- 238000000376 autoradiography Methods 0.000 claims description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 3
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000005992 dihydrobenzisothiazinyl group Chemical group 0.000 claims description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims description 3
- 125000005995 isobenzotetrahydrothienyl group Chemical group 0.000 claims description 3
- 125000005990 isobenzothienyl group Chemical group 0.000 claims description 3
- 125000003151 isocoumarinyl group Chemical group C1(=O)OC(=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 3
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 3
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 claims description 3
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 claims description 3
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims description 3
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000004620 quinolinyl-N-oxide group Chemical group 0.000 claims description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 3
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 3
- 125000004306 triazinyl group Chemical group 0.000 claims description 3
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 125000005993 dihydrobenzisoxazinyl group Chemical group 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 125000005994 isobenzotetrahydrofuranyl group Chemical group 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000001525 receptor binding assay Methods 0.000 claims description 2
- 230000006403 short-term memory Effects 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims 4
- 208000000044 Amnesia Diseases 0.000 claims 2
- 230000004075 alteration Effects 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- NXLQMIPOZVHJFK-UHFFFAOYSA-N 5-(1-methylazetidin-3-yl)oxy-n-(1-methylpyrazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C1N(C)CC1OC1=CC=C(NC=C2C(=O)NC3=NN(C)C=C3)C2=N1 NXLQMIPOZVHJFK-UHFFFAOYSA-N 0.000 claims 1
- ZWSJSDURDMBYLQ-UHFFFAOYSA-N 5-(1-methylpiperidin-4-yl)oxy-n-(1-methylpyrazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC=C(NC=C2C(=O)NC3=NN(C)C=C3)C2=N1 ZWSJSDURDMBYLQ-UHFFFAOYSA-N 0.000 claims 1
- SXZKUSRTMZLERK-UHFFFAOYSA-N 5-(1-methylpiperidin-4-yl)oxy-n-pyridin-4-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC=C(NC=C2C(=O)NC=3C=CN=CC=3)C2=N1 SXZKUSRTMZLERK-UHFFFAOYSA-N 0.000 claims 1
- XDZIOWJQDMIWTP-UHFFFAOYSA-N 5-(1-methylpyrrolidin-3-yl)oxy-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C1N(C)CCC1OC1=CC=C(NC=C2C(=O)NC=3N=CC=CC=3)C2=N1 XDZIOWJQDMIWTP-UHFFFAOYSA-N 0.000 claims 1
- YYWIRLPUXNJQJL-UHFFFAOYSA-N 5-(2-methoxyethoxy)-n-(3-methyl-1,2-oxazol-5-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCOC)=CC=C2NC=C1C(=O)NC1=CC(C)=NO1 YYWIRLPUXNJQJL-UHFFFAOYSA-N 0.000 claims 1
- RZXCFHINAJVRAA-UHFFFAOYSA-N 5-(2-methoxyethoxy)-n-(3-methyl-1,2-thiazol-5-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCOC)=CC=C2NC=C1C(=O)NC1=CC(C)=NS1 RZXCFHINAJVRAA-UHFFFAOYSA-N 0.000 claims 1
- BMLIEOARMJCOEO-UHFFFAOYSA-N 5-(2-methoxyethoxy)-n-(5-methyl-1,2-oxazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCOC)=CC=C2NC=C1C(=O)NC=1C=C(C)ON=1 BMLIEOARMJCOEO-UHFFFAOYSA-N 0.000 claims 1
- KRWIWZHIYZJUKQ-UHFFFAOYSA-N 5-(2-methoxyethoxy)-n-(5-methyl-1h-pyrazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCOC)=CC=C2NC=C1C(=O)NC=1C=C(C)NN=1 KRWIWZHIYZJUKQ-UHFFFAOYSA-N 0.000 claims 1
- WXCBYCXMAHBFQO-UHFFFAOYSA-N 5-(2-morpholin-4-ylethoxy)-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C=1NC2=CC=C(OCCN3CCOCC3)N=C2C=1C(=O)NC1=CC=CC=N1 WXCBYCXMAHBFQO-UHFFFAOYSA-N 0.000 claims 1
- VUVGOXLWIQWNHQ-UHFFFAOYSA-N 5-(3-hydroxy-3-methylbutoxy)-n-(6-methylpyridin-2-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CC1=CC=CC(NC(=O)C=2C3=NC(OCCC(C)(C)O)=CC=C3NC=2)=N1 VUVGOXLWIQWNHQ-UHFFFAOYSA-N 0.000 claims 1
- XBNIAVQEDGQBME-UHFFFAOYSA-N 5-(3-hydroxy-3-methylbutoxy)-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCC(C)(O)C)=CC=C2NC=C1C(=O)NC1=CC=CC=N1 XBNIAVQEDGQBME-UHFFFAOYSA-N 0.000 claims 1
- CGAUNNBDSYXBOF-UHFFFAOYSA-N 5-(3-morpholin-4-ylpropoxy)-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C=1NC2=CC=C(OCCCN3CCOCC3)N=C2C=1C(=O)NC1=CC=CC=N1 CGAUNNBDSYXBOF-UHFFFAOYSA-N 0.000 claims 1
- XLJGAVFPNRWXCA-UHFFFAOYSA-N 5-(3-piperidin-1-ylpropoxy)-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C=1NC2=CC=C(OCCCN3CCCCC3)N=C2C=1C(=O)NC1=CC=CC=N1 XLJGAVFPNRWXCA-UHFFFAOYSA-N 0.000 claims 1
- QWNMDWWPDNRQMT-UHFFFAOYSA-N 5-(4-hydroxy-4-methylpentoxy)-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCCC(C)(O)C)=CC=C2NC=C1C(=O)NC1=CC=CC=N1 QWNMDWWPDNRQMT-UHFFFAOYSA-N 0.000 claims 1
- KLCCIZNKKDBNDH-UHFFFAOYSA-N 5-(4-hydroxybutoxy)-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCCCO)=CC=C2NC=C1C(=O)NC1=CC=CC=N1 KLCCIZNKKDBNDH-UHFFFAOYSA-N 0.000 claims 1
- QYWQLJIHKHPPFM-UHFFFAOYSA-N 5-(ethylamino)-n-(2-fluorophenyl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(NCC)=CC=C2NC=C1C(=O)NC1=CC=CC=C1F QYWQLJIHKHPPFM-UHFFFAOYSA-N 0.000 claims 1
- VPUMCDCOFJVPCI-UHFFFAOYSA-N 5-(ethylamino)-n-(4-methoxyphenyl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(NCC)=CC=C2NC=C1C(=O)NC1=CC=C(OC)C=C1 VPUMCDCOFJVPCI-UHFFFAOYSA-N 0.000 claims 1
- MTHDOPMSQCOXQE-UHFFFAOYSA-N 5-[2-(1-methylpyrrolidin-2-yl)ethoxy]-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CN1CCCC1CCOC1=CC=C(NC=C2C(=O)NC=3N=CC=CC=3)C2=N1 MTHDOPMSQCOXQE-UHFFFAOYSA-N 0.000 claims 1
- RJSFOIHUTNRSJM-UHFFFAOYSA-N 5-[2-(4-methylpiperazin-1-yl)ethoxy]-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C1CN(C)CCN1CCOC1=CC=C(NC=C2C(=O)NC=3N=CC=CC=3)C2=N1 RJSFOIHUTNRSJM-UHFFFAOYSA-N 0.000 claims 1
- SXXRVDPSTHOEFS-UHFFFAOYSA-N 5-[2-(diethylamino)ethoxy]-n-(1-methylpyrazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCN(CC)CC)=CC=C2NC=C1C(=O)NC=1C=CN(C)N=1 SXXRVDPSTHOEFS-UHFFFAOYSA-N 0.000 claims 1
- QQDABHSXACUVLG-UHFFFAOYSA-N 5-[2-(diethylamino)ethoxy]-n-(5-methyl-1,2-oxazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCN(CC)CC)=CC=C2NC=C1C(=O)NC=1C=C(C)ON=1 QQDABHSXACUVLG-UHFFFAOYSA-N 0.000 claims 1
- PEKRKGMBPFWCHH-UHFFFAOYSA-N 5-[2-(diethylamino)ethoxy]-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCN(CC)CC)=CC=C2NC=C1C(=O)NC1=CC=CC=N1 PEKRKGMBPFWCHH-UHFFFAOYSA-N 0.000 claims 1
- WJSRBXHTAJNOTA-UHFFFAOYSA-N 5-[2-(dimethylamino)ethoxy]-n-(1-methylpyrazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCN(C)C)=CC=C2NC=C1C(=O)NC=1C=CN(C)N=1 WJSRBXHTAJNOTA-UHFFFAOYSA-N 0.000 claims 1
- YHQZXVDLTYWIJU-UHFFFAOYSA-N 5-[2-(dimethylamino)ethoxy]-n-(5-methyl-1,2-oxazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCN(C)C)=CC=C2NC=C1C(=O)NC=1C=C(C)ON=1 YHQZXVDLTYWIJU-UHFFFAOYSA-N 0.000 claims 1
- XYTNNYDOEDDGHU-UHFFFAOYSA-N 5-[2-(dimethylamino)ethoxy]-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCN(C)C)=CC=C2NC=C1C(=O)NC1=CC=CC=N1 XYTNNYDOEDDGHU-UHFFFAOYSA-N 0.000 claims 1
- ZDHMOJZRSYHGDD-UHFFFAOYSA-N 5-[3-(3-methylpiperidin-1-yl)propoxy]-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C1C(C)CCCN1CCCOC1=CC=C(NC=C2C(=O)NC=3N=CC=CC=3)C2=N1 ZDHMOJZRSYHGDD-UHFFFAOYSA-N 0.000 claims 1
- CDEYRBWJRBNEJH-UHFFFAOYSA-N 5-[3-(4-methylpiperazin-1-yl)propoxy]-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C1CN(C)CCN1CCCOC1=CC=C(NC=C2C(=O)NC=3N=CC=CC=3)C2=N1 CDEYRBWJRBNEJH-UHFFFAOYSA-N 0.000 claims 1
- CFRBGXIYDHGZDS-UHFFFAOYSA-N 5-[3-(6-azabicyclo[3.2.2]nonan-6-yl)propoxy]-n-(1-methylpyrazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CN1C=CC(NC(=O)C=2C3=NC(OCCCN4C5CCC(CCC5)C4)=CC=C3NC=2)=N1 CFRBGXIYDHGZDS-UHFFFAOYSA-N 0.000 claims 1
- OIGVLUJBEKOPJM-UHFFFAOYSA-N 5-[3-(azetidin-1-yl)propoxy]-n-(1-methylpyrazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CN1C=CC(NC(=O)C=2C3=NC(OCCCN4CCC4)=CC=C3NC=2)=N1 OIGVLUJBEKOPJM-UHFFFAOYSA-N 0.000 claims 1
- YBTBULAXKLJUJR-UHFFFAOYSA-N 5-[3-(azetidin-1-yl)propoxy]-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C=1NC2=CC=C(OCCCN3CCC3)N=C2C=1C(=O)NC1=CC=CC=N1 YBTBULAXKLJUJR-UHFFFAOYSA-N 0.000 claims 1
- XLPLXNHFVDKLJQ-UHFFFAOYSA-N 5-[3-(diethylamino)propoxy]-n-(1-methylpyrazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCCN(CC)CC)=CC=C2NC=C1C(=O)NC=1C=CN(C)N=1 XLPLXNHFVDKLJQ-UHFFFAOYSA-N 0.000 claims 1
- LEWAYLXZGYPICP-UHFFFAOYSA-N 5-[3-(diethylamino)propoxy]-n-(6-ethylpyridin-2-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCCN(CC)CC)=CC=C2NC=C1C(=O)NC1=CC=CC(CC)=N1 LEWAYLXZGYPICP-UHFFFAOYSA-N 0.000 claims 1
- WOSJATPBFFCUDR-UHFFFAOYSA-N 5-[3-(diethylamino)propoxy]-n-(6-methylpyridin-2-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCCN(CC)CC)=CC=C2NC=C1C(=O)NC1=CC=CC(C)=N1 WOSJATPBFFCUDR-UHFFFAOYSA-N 0.000 claims 1
- SGISFWBOMVPOHY-UHFFFAOYSA-N 5-[3-(diethylamino)propoxy]-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCCN(CC)CC)=CC=C2NC=C1C(=O)NC1=CC=CC=N1 SGISFWBOMVPOHY-UHFFFAOYSA-N 0.000 claims 1
- TWVMFAJFXQWSNZ-UHFFFAOYSA-N 5-[3-(dimethylamino)-2,2-dimethylpropoxy]-n-(1-methylpyrazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCC(C)(C)CN(C)C)=CC=C2NC=C1C(=O)NC=1C=CN(C)N=1 TWVMFAJFXQWSNZ-UHFFFAOYSA-N 0.000 claims 1
- OPXNVNATDUCALK-UHFFFAOYSA-N 5-[3-(dimethylamino)-2,2-dimethylpropoxy]-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCC(C)(C)CN(C)C)=CC=C2NC=C1C(=O)NC1=CC=CC=N1 OPXNVNATDUCALK-UHFFFAOYSA-N 0.000 claims 1
- CLUOOJXTIAQZKW-UHFFFAOYSA-N 5-[3-(dimethylamino)propoxy]-n-(1-ethylpyrazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CCN1C=CC(NC(=O)C=2C3=NC(OCCCN(C)C)=CC=C3NC=2)=N1 CLUOOJXTIAQZKW-UHFFFAOYSA-N 0.000 claims 1
- RDTZVCJWAYWZGO-UHFFFAOYSA-N 5-[3-(dimethylamino)propoxy]-n-(1-methylpyrazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCCN(C)C)=CC=C2NC=C1C(=O)NC=1C=CN(C)N=1 RDTZVCJWAYWZGO-UHFFFAOYSA-N 0.000 claims 1
- PACOXFCRZJTDCR-UHFFFAOYSA-N 5-[3-(dimethylamino)propoxy]-n-(1-propylpyrazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CCCN1C=CC(NC(=O)C=2C3=NC(OCCCN(C)C)=CC=C3NC=2)=N1 PACOXFCRZJTDCR-UHFFFAOYSA-N 0.000 claims 1
- GNPZSHUHJJOKPR-UHFFFAOYSA-N 5-[3-(dimethylamino)propoxy]-n-(3-fluorophenyl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCCN(C)C)=CC=C2NC=C1C(=O)NC1=CC=CC(F)=C1 GNPZSHUHJJOKPR-UHFFFAOYSA-N 0.000 claims 1
- CLGMAPDJGUGBAN-UHFFFAOYSA-N 5-[3-(dimethylamino)propoxy]-n-(3-methyl-1,2-oxazol-5-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCCN(C)C)=CC=C2NC=C1C(=O)NC1=CC(C)=NO1 CLGMAPDJGUGBAN-UHFFFAOYSA-N 0.000 claims 1
- SRSHRDDBRASUQK-UHFFFAOYSA-N 5-[3-(dimethylamino)propoxy]-n-(4,6-dimethylpyridin-2-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCCN(C)C)=CC=C2NC=C1C(=O)NC1=CC(C)=CC(C)=N1 SRSHRDDBRASUQK-UHFFFAOYSA-N 0.000 claims 1
- PBGGNZOJHZGKSI-UHFFFAOYSA-N 5-[3-(dimethylamino)propoxy]-n-(5-methyl-1,3,4-thiadiazol-2-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCCN(C)C)=CC=C2NC=C1C(=O)NC1=NN=C(C)S1 PBGGNZOJHZGKSI-UHFFFAOYSA-N 0.000 claims 1
- MRVAYBXHPBMXQO-UHFFFAOYSA-N 5-[3-(dimethylamino)propoxy]-n-(6-methoxypyridin-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC=C1NC(=O)C1=CNC2=CC=C(OCCCN(C)C)N=C12 MRVAYBXHPBMXQO-UHFFFAOYSA-N 0.000 claims 1
- ZUTPSYSGUGHSOJ-UHFFFAOYSA-N 5-[3-(dimethylamino)propoxy]-n-(6-methylpyridin-2-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCCN(C)C)=CC=C2NC=C1C(=O)NC1=CC=CC(C)=N1 ZUTPSYSGUGHSOJ-UHFFFAOYSA-N 0.000 claims 1
- OOBNHMKHOWSLJZ-UHFFFAOYSA-N 5-[3-(dimethylamino)propoxy]-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCCN(C)C)=CC=C2NC=C1C(=O)NC1=CC=CC=N1 OOBNHMKHOWSLJZ-UHFFFAOYSA-N 0.000 claims 1
- CTQACPKJLGPNEM-UHFFFAOYSA-N 5-[3-(dimethylamino)propoxy]-n-pyrimidin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCCN(C)C)=CC=C2NC=C1C(=O)NC1=NC=CC=N1 CTQACPKJLGPNEM-UHFFFAOYSA-N 0.000 claims 1
- UBGFZLUEJOOUSV-UHFFFAOYSA-N 5-[4-(diethylamino)butoxy]-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCCCN(CC)CC)=CC=C2NC=C1C(=O)NC1=CC=CC=N1 UBGFZLUEJOOUSV-UHFFFAOYSA-N 0.000 claims 1
- DQOAOOOEGQTUAA-UHFFFAOYSA-N 5-[4-(dimethylamino)butoxy]-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCCCCN(C)C)=CC=C2NC=C1C(=O)NC1=CC=CC=N1 DQOAOOOEGQTUAA-UHFFFAOYSA-N 0.000 claims 1
- WNPNBLTUTHKCOZ-UHFFFAOYSA-N 5-ethoxy-n-(1-ethylpyrazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCC)=CC=C2NC=C1C(=O)NC=1C=CN(CC)N=1 WNPNBLTUTHKCOZ-UHFFFAOYSA-N 0.000 claims 1
- KFJZYMCLNYYCTD-UHFFFAOYSA-N 5-ethoxy-n-(2-fluorophenyl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCC)=CC=C2NC=C1C(=O)NC1=CC=CC=C1F KFJZYMCLNYYCTD-UHFFFAOYSA-N 0.000 claims 1
- YXUPSDNPMYDXSB-UHFFFAOYSA-N 5-ethoxy-n-(3-methyl-1,2-oxazol-5-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCC)=CC=C2NC=C1C(=O)NC1=CC(C)=NO1 YXUPSDNPMYDXSB-UHFFFAOYSA-N 0.000 claims 1
- VTKQXOVTUMMFPX-UHFFFAOYSA-N 5-ethoxy-n-(3-methyl-1,2-thiazol-5-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCC)=CC=C2NC=C1C(=O)NC1=CC(C)=NS1 VTKQXOVTUMMFPX-UHFFFAOYSA-N 0.000 claims 1
- VIVSPPPZBPQZJO-UHFFFAOYSA-N 5-ethoxy-n-(4-methoxyphenyl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCC)=CC=C2NC=C1C(=O)NC1=CC=C(OC)C=C1 VIVSPPPZBPQZJO-UHFFFAOYSA-N 0.000 claims 1
- AWYIOSBJDGFYRP-UHFFFAOYSA-N 5-ethoxy-n-(5-methyl-1,2-oxazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCC)=CC=C2NC=C1C(=O)NC=1C=C(C)ON=1 AWYIOSBJDGFYRP-UHFFFAOYSA-N 0.000 claims 1
- OBHRCSIWEVZKPW-UHFFFAOYSA-N 5-ethoxy-n-(5-methyl-1h-pyrazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCC)=CC=C2NC=C1C(=O)NC=1C=C(C)NN=1 OBHRCSIWEVZKPW-UHFFFAOYSA-N 0.000 claims 1
- LOKQCAQHPJAORD-UHFFFAOYSA-N 5-ethoxy-n-[3-(hydroxymethyl)phenyl]-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCC)=CC=C2NC=C1C(=O)NC1=CC=CC(CO)=C1 LOKQCAQHPJAORD-UHFFFAOYSA-N 0.000 claims 1
- WEFIJMODDKYJAE-UHFFFAOYSA-N 5-ethoxy-n-[4-(2-ethoxyethoxy)phenyl]-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C1=CC(OCCOCC)=CC=C1NC(=O)C1=CNC2=CC=C(OCC)N=C12 WEFIJMODDKYJAE-UHFFFAOYSA-N 0.000 claims 1
- AHGZVQLUFGLYEB-UHFFFAOYSA-N 5-ethoxy-n-[4-(2-hydroxyethyl)phenyl]-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCC)=CC=C2NC=C1C(=O)NC1=CC=C(CCO)C=C1 AHGZVQLUFGLYEB-UHFFFAOYSA-N 0.000 claims 1
- QKDJYBKKBRLHMW-UHFFFAOYSA-N 5-ethoxy-n-[4-(2-pyrrolidin-1-ylethyl)phenyl]-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCC)=CC=C2NC=C1C(=O)NC(C=C1)=CC=C1CCN1CCCC1 QKDJYBKKBRLHMW-UHFFFAOYSA-N 0.000 claims 1
- CDEZXGBBIKWPLN-UHFFFAOYSA-N 5-ethoxy-n-[6-(oxolan-3-yloxy)pyridin-3-yl]-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCC)=CC=C2NC=C1C(=O)NC(C=N1)=CC=C1OC1CCOC1 CDEZXGBBIKWPLN-UHFFFAOYSA-N 0.000 claims 1
- GHFZKWXBNRRJNR-UHFFFAOYSA-N 5-ethoxy-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCC)=CC=C2NC=C1C(=O)NC1=CC=CC=N1 GHFZKWXBNRRJNR-UHFFFAOYSA-N 0.000 claims 1
- VAXZDWVWPDAOOA-UHFFFAOYSA-N 5-methoxy-n-(4-methoxyphenyl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)C1=CNC2=CC=C(OC)N=C12 VAXZDWVWPDAOOA-UHFFFAOYSA-N 0.000 claims 1
- PUBDYQQPPZWTIJ-UHFFFAOYSA-N 5-methoxy-n-(pyridin-2-ylmethyl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OC)=CC=C2NC=C1C(=O)NCC1=CC=CC=N1 PUBDYQQPPZWTIJ-UHFFFAOYSA-N 0.000 claims 1
- HUQWSMHYMSMYIU-UHFFFAOYSA-N 5-methoxy-n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OC)=CC=C2NC=C1C(=O)NC1=CC=CC=N1 HUQWSMHYMSMYIU-UHFFFAOYSA-N 0.000 claims 1
- USFRJXOTTYTLCZ-UHFFFAOYSA-N 6-methyl-n-(1-propylpyrazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CCCN1C=CC(NC(=O)C=2C3=NC=C(C)C=C3NC=2)=N1 USFRJXOTTYTLCZ-UHFFFAOYSA-N 0.000 claims 1
- UEPIDBBRHQBQBQ-UHFFFAOYSA-N 6-methyl-n-(5-propoxypyridin-2-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound N1=CC(OCCC)=CC=C1NC(=O)C1=CNC2=CC(C)=CN=C12 UEPIDBBRHQBQBQ-UHFFFAOYSA-N 0.000 claims 1
- LWQJQSQPSVJTCW-UHFFFAOYSA-N 6-methyl-n-pyrazin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C=1NC2=CC(C)=CN=C2C=1C(=O)NC1=CN=CC=N1 LWQJQSQPSVJTCW-UHFFFAOYSA-N 0.000 claims 1
- UBEZTVPUGZVMRT-UHFFFAOYSA-N 6-methyl-n-pyridin-3-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C=1NC2=CC(C)=CN=C2C=1C(=O)NC1=CC=CN=C1 UBEZTVPUGZVMRT-UHFFFAOYSA-N 0.000 claims 1
- CQFBITBKJZLRND-UHFFFAOYSA-N 7-chloro-n-(2-fluorophenyl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound FC1=CC=CC=C1NC(=O)C1=CNC2=C(Cl)C=CN=C12 CQFBITBKJZLRND-UHFFFAOYSA-N 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 claims 1
- IQDQOWNASWCFRM-UHFFFAOYSA-N n-(1-butylpyrazol-3-yl)-5-(3-pyridin-2-ylpropoxy)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CCCCN1C=CC(NC(=O)C=2C3=NC(OCCCC=4N=CC=CC=4)=CC=C3NC=2)=N1 IQDQOWNASWCFRM-UHFFFAOYSA-N 0.000 claims 1
- RVQJOXGPNMYUFJ-UHFFFAOYSA-N n-(1-butylpyrazol-3-yl)-5-[3-(dimethylamino)propoxy]-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CCCCN1C=CC(NC(=O)C=2C3=NC(OCCCN(C)C)=CC=C3NC=2)=N1 RVQJOXGPNMYUFJ-UHFFFAOYSA-N 0.000 claims 1
- AZYQLRGXCSGZQZ-UHFFFAOYSA-N n-(1-ethylpyrazol-3-yl)-5-(3-pyridin-2-ylpropoxy)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CCN1C=CC(NC(=O)C=2C3=NC(OCCCC=4N=CC=CC=4)=CC=C3NC=2)=N1 AZYQLRGXCSGZQZ-UHFFFAOYSA-N 0.000 claims 1
- AMLBBURTZVJTOU-UHFFFAOYSA-N n-(1-ethylpyrazol-3-yl)-5-propan-2-yloxy-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CCN1C=CC(NC(=O)C=2C3=NC(OC(C)C)=CC=C3NC=2)=N1 AMLBBURTZVJTOU-UHFFFAOYSA-N 0.000 claims 1
- KJFAJYLTCBMMTA-UHFFFAOYSA-N n-(1-methylpyrazol-3-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CN1C=CC(NC(=O)C=2C3=NC=CC=C3NC=2)=N1 KJFAJYLTCBMMTA-UHFFFAOYSA-N 0.000 claims 1
- LQUMAELYDSSTOP-UHFFFAOYSA-N n-(1-methylpyrazol-3-yl)-5-(1-methylpyrrolidin-3-yl)oxy-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C1N(C)CCC1OC1=CC=C(NC=C2C(=O)NC3=NN(C)C=C3)C2=N1 LQUMAELYDSSTOP-UHFFFAOYSA-N 0.000 claims 1
- CNNKFVROFAZVAU-UHFFFAOYSA-N n-(1-methylpyrazol-3-yl)-5-(2-morpholin-4-ylethoxy)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CN1C=CC(NC(=O)C=2C3=NC(OCCN4CCOCC4)=CC=C3NC=2)=N1 CNNKFVROFAZVAU-UHFFFAOYSA-N 0.000 claims 1
- XNHSCZXPNGESSZ-UHFFFAOYSA-N n-(1-methylpyrazol-3-yl)-5-(2-pyrrolidin-1-ylethoxy)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CN1C=CC(NC(=O)C=2C3=NC(OCCN4CCCC4)=CC=C3NC=2)=N1 XNHSCZXPNGESSZ-UHFFFAOYSA-N 0.000 claims 1
- RBPYMCCOFULESL-UHFFFAOYSA-N n-(1-methylpyrazol-3-yl)-5-(3-morpholin-4-ylpropoxy)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CN1C=CC(NC(=O)C=2C3=NC(OCCCN4CCOCC4)=CC=C3NC=2)=N1 RBPYMCCOFULESL-UHFFFAOYSA-N 0.000 claims 1
- KZLDLXJVHOZLPK-UHFFFAOYSA-N n-(1-methylpyrazol-3-yl)-5-(3-piperidin-1-ylpropoxy)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CN1C=CC(NC(=O)C=2C3=NC(OCCCN4CCCCC4)=CC=C3NC=2)=N1 KZLDLXJVHOZLPK-UHFFFAOYSA-N 0.000 claims 1
- WQAOMMRIHDCEGB-UHFFFAOYSA-N n-(1-methylpyrazol-3-yl)-5-(3-pyridin-2-ylpropoxy)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CN1C=CC(NC(=O)C=2C3=NC(OCCCC=4N=CC=CC=4)=CC=C3NC=2)=N1 WQAOMMRIHDCEGB-UHFFFAOYSA-N 0.000 claims 1
- KYNXPQXECRMKHX-UHFFFAOYSA-N n-(1-methylpyrazol-3-yl)-5-(3-pyrrol-1-ylpropoxy)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CN1C=CC(NC(=O)C=2C3=NC(OCCCN4C=CC=C4)=CC=C3NC=2)=N1 KYNXPQXECRMKHX-UHFFFAOYSA-N 0.000 claims 1
- CPAGGUOKQRPVLQ-UHFFFAOYSA-N n-(1-methylpyrazol-3-yl)-5-oxo-1,4-dihydropyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CN1C=CC(NC(=O)C=2C=3NC(=O)C=CC=3NC=2)=N1 CPAGGUOKQRPVLQ-UHFFFAOYSA-N 0.000 claims 1
- NPRIYWHZOQGWGQ-UHFFFAOYSA-N n-(1-propylpyrazol-3-yl)-5-(3-pyridin-2-ylpropoxy)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CCCN1C=CC(NC(=O)C=2C3=NC(OCCCC=4N=CC=CC=4)=CC=C3NC=2)=N1 NPRIYWHZOQGWGQ-UHFFFAOYSA-N 0.000 claims 1
- KLWXUBNNUYKJLB-UHFFFAOYSA-N n-(2-fluorophenyl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound FC1=CC=CC=C1NC(=O)C1=CNC2=CC=CN=C12 KLWXUBNNUYKJLB-UHFFFAOYSA-N 0.000 claims 1
- VZOQCGLPGIOKHU-UHFFFAOYSA-N n-(2-fluorophenyl)-5-methoxy-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OC)=CC=C2NC=C1C(=O)NC1=CC=CC=C1F VZOQCGLPGIOKHU-UHFFFAOYSA-N 0.000 claims 1
- AGIKECHMDXYIQE-UHFFFAOYSA-N n-(3-fluoro-4-methoxyphenyl)-5-propan-2-yloxy-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C1=C(F)C(OC)=CC=C1NC(=O)C1=CNC2=CC=C(OC(C)C)N=C12 AGIKECHMDXYIQE-UHFFFAOYSA-N 0.000 claims 1
- XZHVOVQPYMXMAE-UHFFFAOYSA-N n-(3-fluorophenyl)-5-propan-2-yloxy-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OC(C)C)=CC=C2NC=C1C(=O)NC1=CC=CC(F)=C1 XZHVOVQPYMXMAE-UHFFFAOYSA-N 0.000 claims 1
- QGJVSJXCDLIMJS-UHFFFAOYSA-N n-(3-methyl-1,2-oxazol-5-yl)-5-propan-2-yloxy-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OC(C)C)=CC=C2NC=C1C(=O)NC1=CC(C)=NO1 QGJVSJXCDLIMJS-UHFFFAOYSA-N 0.000 claims 1
- DRSFGUGQOGKOFJ-UHFFFAOYSA-N n-(3-methyl-1,2-thiazol-5-yl)-5-propan-2-yloxy-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OC(C)C)=CC=C2NC=C1C(=O)NC1=CC(C)=NS1 DRSFGUGQOGKOFJ-UHFFFAOYSA-N 0.000 claims 1
- IILVZENHPYOMMK-UHFFFAOYSA-N n-(3-propyl-1,2,4-thiadiazol-5-yl)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CCCC1=NSC(NC(=O)C=2C3=NC=CC=C3NC=2)=N1 IILVZENHPYOMMK-UHFFFAOYSA-N 0.000 claims 1
- HARQKKAEKQUYNO-UHFFFAOYSA-N n-(4,6-dimethylpyridin-2-yl)-5-(3-hydroxy-3-methylbutoxy)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound CC1=CC(C)=NC(NC(=O)C=2C3=NC(OCCC(C)(C)O)=CC=C3NC=2)=C1 HARQKKAEKQUYNO-UHFFFAOYSA-N 0.000 claims 1
- VCYFNNWTULAHFH-UHFFFAOYSA-N n-(4-methoxyphenyl)-6-methyl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)C1=CNC2=CC(C)=CN=C12 VCYFNNWTULAHFH-UHFFFAOYSA-N 0.000 claims 1
- BHMMCAHVCXLGAI-UHFFFAOYSA-N n-(5-chloropyridin-2-yl)-5-ethoxy-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCC)=CC=C2NC=C1C(=O)NC1=CC=C(Cl)C=N1 BHMMCAHVCXLGAI-UHFFFAOYSA-N 0.000 claims 1
- KYJBRTSLCDEXNC-UHFFFAOYSA-N n-(5-methyl-1,2-oxazol-3-yl)-5-(1-methylpiperidin-4-yl)oxy-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C1CN(C)CCC1OC1=CC=C(NC=C2C(=O)NC3=NOC(C)=C3)C2=N1 KYJBRTSLCDEXNC-UHFFFAOYSA-N 0.000 claims 1
- RJRGRWVEJGYIMB-UHFFFAOYSA-N n-(5-methyl-1,2-oxazol-3-yl)-5-(1-methylpyrrolidin-3-yl)oxy-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C1N(C)CCC1OC1=CC=C(NC=C2C(=O)NC3=NOC(C)=C3)C2=N1 RJRGRWVEJGYIMB-UHFFFAOYSA-N 0.000 claims 1
- XXHYWQAHAVVTOA-UHFFFAOYSA-N n-(5-methyl-1,2-oxazol-3-yl)-5-(2-pyrrolidin-1-ylethoxy)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound O1C(C)=CC(NC(=O)C=2C3=NC(OCCN4CCCC4)=CC=C3NC=2)=N1 XXHYWQAHAVVTOA-UHFFFAOYSA-N 0.000 claims 1
- VPTRWVQXGJTBHN-UHFFFAOYSA-N n-(5-methyl-1,2-oxazol-3-yl)-5-propan-2-yloxy-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OC(C)C)=CC=C2NC=C1C(=O)NC=1C=C(C)ON=1 VPTRWVQXGJTBHN-UHFFFAOYSA-N 0.000 claims 1
- PSZQHRDVCFTJFC-UHFFFAOYSA-N n-(5-methyl-1h-pyrazol-3-yl)-5-propan-2-yloxy-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OC(C)C)=CC=C2NC=C1C(=O)NC=1C=C(C)NN=1 PSZQHRDVCFTJFC-UHFFFAOYSA-N 0.000 claims 1
- QPXBTYCQIUDAAZ-UHFFFAOYSA-N n-(6-bromopyridin-3-yl)-5-ethoxy-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCC)=CC=C2NC=C1C(=O)NC1=CC=C(Br)N=C1 QPXBTYCQIUDAAZ-UHFFFAOYSA-N 0.000 claims 1
- JEQBUHDIELBLHJ-UHFFFAOYSA-N n-(6-methoxypyrazin-2-yl)-5-(1-methylpiperidin-4-yl)oxy-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound COC1=CN=CC(NC(=O)C=2C3=NC(OC4CCN(C)CC4)=CC=C3NC=2)=N1 JEQBUHDIELBLHJ-UHFFFAOYSA-N 0.000 claims 1
- VRULZWPRUHOAPF-UHFFFAOYSA-N n-[4-[2-(diethylamino)ethyl]phenyl]-5-ethoxy-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCC)=CC=C2NC=C1C(=O)NC1=CC=C(CCN(CC)CC)C=C1 VRULZWPRUHOAPF-UHFFFAOYSA-N 0.000 claims 1
- OWBKWZGQIBWMSS-UHFFFAOYSA-N n-[4-[3-(methanesulfonamido)propoxy]phenyl]-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C1=CC(OCCCNS(=O)(=O)C)=CC=C1NC(=O)C1=CNC2=CC=CN=C12 OWBKWZGQIBWMSS-UHFFFAOYSA-N 0.000 claims 1
- VIEJWJLVFAMLTQ-UHFFFAOYSA-N n-[6-[3-(diethylamino)propoxy]pyridin-3-yl]-5-ethoxy-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C12=NC(OCC)=CC=C2NC=C1C(=O)NC1=CC=C(OCCCN(CC)CC)N=C1 VIEJWJLVFAMLTQ-UHFFFAOYSA-N 0.000 claims 1
- OQZFULXWBKRMFK-UHFFFAOYSA-N n-[6-[3-(diethylamino)propoxy]pyridin-3-yl]-5-methoxy-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C1=NC(OCCCN(CC)CC)=CC=C1NC(=O)C1=CNC2=CC=C(OC)N=C12 OQZFULXWBKRMFK-UHFFFAOYSA-N 0.000 claims 1
- RURXSDZKKASHSF-UHFFFAOYSA-N n-pyridin-2-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C=1NC2=CC=CN=C2C=1C(=O)NC1=CC=CC=N1 RURXSDZKKASHSF-UHFFFAOYSA-N 0.000 claims 1
- NFOMGXHFYLAQLO-UHFFFAOYSA-N n-pyridin-2-yl-5-(2-pyrrolidin-1-ylethoxy)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C=1NC2=CC=C(OCCN3CCCC3)N=C2C=1C(=O)NC1=CC=CC=N1 NFOMGXHFYLAQLO-UHFFFAOYSA-N 0.000 claims 1
- WOPNAAFEBYTKSQ-UHFFFAOYSA-N n-pyridin-2-yl-5-(3-pyridin-2-ylpropoxy)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C=1NC2=CC=C(OCCCC=3N=CC=CC=3)N=C2C=1C(=O)NC1=CC=CC=N1 WOPNAAFEBYTKSQ-UHFFFAOYSA-N 0.000 claims 1
- ABXKXRBQKXGMNS-UHFFFAOYSA-N n-pyridin-2-yl-5-(3-pyrrol-1-ylpropoxy)-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C=1NC2=CC=C(OCCCN3C=CC=C3)N=C2C=1C(=O)NC1=CC=CC=N1 ABXKXRBQKXGMNS-UHFFFAOYSA-N 0.000 claims 1
- QZNPXKRALPFXPR-UHFFFAOYSA-N n-pyridin-2-ylpyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC1=CC=CC=N1 QZNPXKRALPFXPR-UHFFFAOYSA-N 0.000 claims 1
- WTTQCJZUJSVBJX-UHFFFAOYSA-N n-quinolin-8-yl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical compound C1=CN=C2C(C(NC=3C4=NC=CC=C4C=CC=3)=O)=CNC2=C1 WTTQCJZUJSVBJX-UHFFFAOYSA-N 0.000 claims 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 abstract description 22
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 210000003169 central nervous system Anatomy 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 abstract description 9
- 239000003446 ligand Substances 0.000 abstract description 9
- 238000001727 in vivo Methods 0.000 abstract description 5
- PMBKVWCLVTYNAG-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical class C1=CN=C2C(C(=O)N)=CNC2=C1 PMBKVWCLVTYNAG-UHFFFAOYSA-N 0.000 abstract description 3
- 244000144972 livestock Species 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- 238000005481 NMR spectroscopy Methods 0.000 description 18
- 239000000556 agonist Substances 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 15
- 239000000523 sample Substances 0.000 description 14
- 239000002253 acid Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000009471 action Effects 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 231100000252 nontoxic Toxicity 0.000 description 9
- 230000003000 nontoxic effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 208000010877 cognitive disease Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical group [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 208000028698 Cognitive impairment Diseases 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000007859 condensation product Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 229920000728 polyester Polymers 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 208000015114 central nervous system disease Diseases 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 239000013068 control sample Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- UWXNXJYYYLVLMZ-UHFFFAOYSA-N ethyl 1-hydroxy-6-methylpyrrolo[3,2-b]pyridine-3-carboxylate Chemical compound CC1=CN=C2C(C(=O)OCC)=CN(O)C2=C1 UWXNXJYYYLVLMZ-UHFFFAOYSA-N 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 210000000287 oocyte Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229910052722 tritium Inorganic materials 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 208000011688 Generalised anxiety disease Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000000211 autoradiogram Methods 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000010908 decantation Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- KUVQYVAQCIVWPY-UHFFFAOYSA-N ethyl 2-(5-methyl-3-nitropyridin-2-yl)acetate Chemical compound CCOC(=O)CC1=NC=C(C)C=C1[N+]([O-])=O KUVQYVAQCIVWPY-UHFFFAOYSA-N 0.000 description 3
- ZASIDYCYCNXKHC-UHFFFAOYSA-N ethyl 6-methyl-1h-pyrrolo[3,2-b]pyridine-3-carboxylate Chemical compound CC1=CN=C2C(C(=O)OCC)=CNC2=C1 ZASIDYCYCNXKHC-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 208000029364 generalized anxiety disease Diseases 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 206010027175 memory impairment Diseases 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- SHCWQWRTKPNTEM-UHFFFAOYSA-N 2,6-dichloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1Cl SHCWQWRTKPNTEM-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- LUAJUWOJEFFNFE-UHFFFAOYSA-N 2-chloro-5-methyl-3-nitropyridine Chemical compound CC1=CN=C(Cl)C([N+]([O-])=O)=C1 LUAJUWOJEFFNFE-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- 208000008811 Agoraphobia Diseases 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XBLVHTDFJBKJLG-UHFFFAOYSA-N Ethyl nicotinate Chemical compound CCOC(=O)C1=CC=CN=C1 XBLVHTDFJBKJLG-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000013200 Stress disease Diseases 0.000 description 2
- 208000003028 Stuttering Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000007000 age related cognitive decline Effects 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000005576 amination reaction Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- AEPARRPAHKKTID-UHFFFAOYSA-N diethyl 2-(5-methyl-3-nitropyridin-2-yl)propanedioate Chemical compound CCOC(=O)C(C(=O)OCC)C1=NC=C(C)C=C1[N+]([O-])=O AEPARRPAHKKTID-UHFFFAOYSA-N 0.000 description 2
- YHYAAVMWOMIJEX-UHFFFAOYSA-N diethyl 2-(6-chloro-3-nitropyridin-2-yl)propanedioate Chemical compound CCOC(=O)C(C(=O)OCC)C1=NC(Cl)=CC=C1[N+]([O-])=O YHYAAVMWOMIJEX-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- JRVDUQHYJGRGCI-UHFFFAOYSA-N ethyl 2-(6-chloro-3-nitropyridin-2-yl)acetate Chemical compound CCOC(=O)CC1=NC(Cl)=CC=C1[N+]([O-])=O JRVDUQHYJGRGCI-UHFFFAOYSA-N 0.000 description 2
- HCVYCOJWGFTSJV-UHFFFAOYSA-N ethyl 2-[6-(1-methylpiperidin-4-yl)oxy-3-nitropyridin-2-yl]acetate Chemical compound C1=C([N+]([O-])=O)C(CC(=O)OCC)=NC(OC2CCN(C)CC2)=C1 HCVYCOJWGFTSJV-UHFFFAOYSA-N 0.000 description 2
- MGIZJWIJVKXBDL-UHFFFAOYSA-N ethyl 3-(dimethylamino)-2-(5-methyl-3-nitropyridin-2-yl)prop-2-enoate Chemical compound CCOC(=O)C(=CN(C)C)C1=NC=C(C)C=C1[N+]([O-])=O MGIZJWIJVKXBDL-UHFFFAOYSA-N 0.000 description 2
- MUPKYSOWRIVQBL-UHFFFAOYSA-N ethyl 3-(dimethylamino)-2-[6-(1-methylpiperidin-4-yl)oxy-3-nitropyridin-2-yl]prop-2-enoate Chemical compound C1=C([N+]([O-])=O)C(C(=CN(C)C)C(=O)OCC)=NC(OC2CCN(C)CC2)=C1 MUPKYSOWRIVQBL-UHFFFAOYSA-N 0.000 description 2
- PAOSNMHABBSWFH-UHFFFAOYSA-N ethyl 5-(1-methylpiperidin-4-yl)oxy-1h-pyrrolo[3,2-b]pyridine-3-carboxylate Chemical compound N1=C2C(C(=O)OCC)=CNC2=CC=C1OC1CCN(C)CC1 PAOSNMHABBSWFH-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000055647 human CSF2RB Human genes 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940030980 inova Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- HXRAMSFGUAOAJR-UHFFFAOYSA-N n,n,n',n'-tetramethyl-1-[(2-methylpropan-2-yl)oxy]methanediamine Chemical compound CN(C)C(N(C)C)OC(C)(C)C HXRAMSFGUAOAJR-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical compound CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 125000005925 3-methylpentyloxy group Chemical group 0.000 description 1
- 239000003483 4 aminobutyric acid A receptor stimulating agent Substances 0.000 description 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- DJZNQJZKCIDPTB-UHFFFAOYSA-N 5-methyl-1h-pyrrolo[3,2-b]pyridine-3-carboxamide Chemical class CC1=CC=C2NC=C(C(N)=O)C2=N1 DJZNQJZKCIDPTB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002758 Anticipatory anxiety Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- MUPKYSOWRIVQBL-OWBHPGMISA-N CCOC(/C(/c1nc(OC2CCN(C)CC2)ccc1[N+]([O-])=O)=C\N(C)C)=O Chemical compound CCOC(/C(/c1nc(OC2CCN(C)CC2)ccc1[N+]([O-])=O)=C\N(C)C)=O MUPKYSOWRIVQBL-OWBHPGMISA-N 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102100021752 Corticoliberin Human genes 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 description 1
- 102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 208000003870 Drug Overdose Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical compound CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000013716 Motor tics Diseases 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 206010033296 Overdoses Diseases 0.000 description 1
- 208000006199 Parasomnias Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- LHNKBXRFNPMIBR-UHFFFAOYSA-N Picrotoxin Natural products CC(C)(O)C1(O)C2OC(=O)C1C3(O)C4OC4C5C(=O)OC2C35C LHNKBXRFNPMIBR-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 208000000810 Separation Anxiety Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000008234 Tics Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 208000026345 acute stress disease Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000025748 atypical depressive disease Diseases 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000037411 cognitive enhancing Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000005257 cortical tissue Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- LXQXGFPPYLKKSD-UHFFFAOYSA-L disodium;2,2-diethylpropanedioate Chemical compound [Na+].[Na+].CCC(CC)(C([O-])=O)C([O-])=O LXQXGFPPYLKKSD-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 231100000725 drug overdose Toxicity 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000004401 flow injection analysis Methods 0.000 description 1
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 1
- 229960004381 flumazenil Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229940053999 hypnotics and sedatives melatonin receptor agonists Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000011977 language disease Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000010291 membrane polarization Effects 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000005484 neopentoxy group Chemical group 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- VJKUPQSHOVKBCO-AHMKVGDJSA-N picrotoxin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000216 proconvulsive effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000004892 pyridazines Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000025874 separation anxiety disease Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000003567 signal transduction assay Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 150000003413 spiro compounds Chemical class 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- 125000004952 trihaloalkoxy group Chemical group 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33302701P | 2001-11-19 | 2001-11-19 | |
| PCT/US2002/037157 WO2003044018A1 (en) | 2001-11-19 | 2002-11-19 | 1h-pyrrolo[3,2-b]pyridine-3-carboxylic acid amides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005516901A true JP2005516901A (ja) | 2005-06-09 |
| JP2005516901A5 JP2005516901A5 (enExample) | 2006-01-19 |
Family
ID=23300941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003545655A Pending JP2005516901A (ja) | 2001-11-19 | 2002-11-19 | １Ｈ−ピロロ［３，２−ｂ］ピリジン−３−カルボン酸アミド化合物 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1453831A1 (enExample) |
| JP (1) | JP2005516901A (enExample) |
| AU (1) | AU2002366092A1 (enExample) |
| BR (1) | BR0214301A (enExample) |
| CA (1) | CA2467542A1 (enExample) |
| MX (1) | MXPA04004711A (enExample) |
| WO (1) | WO2003044018A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2865208B1 (fr) * | 2004-01-16 | 2009-01-16 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique |
| FR2890072A1 (fr) * | 2005-09-01 | 2007-03-02 | Fournier S A Sa Lab | Nouveaux composesde pyrrolopyridine |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| WO2014196793A1 (en) | 2013-06-05 | 2014-12-11 | C&C Research Laboratories | Heterocyclic derivatives and use thereof |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| CN116102549B (zh) * | 2021-11-09 | 2025-02-11 | 暨南大学 | 5-醛基杂环酰胺类化合物及其应用 |
| WO2023082044A1 (zh) * | 2021-11-09 | 2023-05-19 | 暨南大学 | 5-醛基杂环酰胺类化合物及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5750702A (en) * | 1993-10-27 | 1998-05-12 | Neurogen Corporation | Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands |
-
2002
- 2002-11-19 JP JP2003545655A patent/JP2005516901A/ja active Pending
- 2002-11-19 CA CA002467542A patent/CA2467542A1/en not_active Abandoned
- 2002-11-19 AU AU2002366092A patent/AU2002366092A1/en not_active Abandoned
- 2002-11-19 MX MXPA04004711A patent/MXPA04004711A/es active IP Right Grant
- 2002-11-19 WO PCT/US2002/037157 patent/WO2003044018A1/en not_active Ceased
- 2002-11-19 EP EP02803679A patent/EP1453831A1/en not_active Withdrawn
- 2002-11-19 BR BR0214301-1A patent/BR0214301A/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1453831A1 (en) | 2004-09-08 |
| WO2003044018A1 (en) | 2003-05-30 |
| MXPA04004711A (es) | 2005-08-16 |
| AU2002366092A1 (en) | 2003-06-10 |
| CA2467542A1 (en) | 2003-05-30 |
| BR0214301A (pt) | 2004-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1177177B1 (en) | Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands | |
| EP1228069B1 (en) | Bicyclic and tricyclic heteroaromatic compounds | |
| US6828329B2 (en) | Aryl fused substituted 4-oxy-pyridines | |
| US20040110778A1 (en) | Heterocyclic compounds as ligands of the GABAA receptor | |
| US6656941B2 (en) | Aryl substituted tetrahydroindazoles | |
| CN104844578B (zh) | 5元杂环酰胺及相关的化合物 | |
| WO2002002557A2 (en) | 2-phenylimidazo[1,2-a]pyridine derivatives: a new class of gaba brain receptor ligands | |
| US6723332B2 (en) | Oxomidazopyridine-carboxamides | |
| JP2003508385A (ja) | 縮合ピロールカルボキサミド：ｇａｂａ脳受容体リガンド | |
| JP2005525333A (ja) | 置換縮合ピラゾールカルボン酸アリールアミド及び関連化合物 | |
| US6743817B2 (en) | Substituted fused pyrroleimines and pyrazoleimines | |
| US6861529B2 (en) | Cycloalkypyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives | |
| WO2003044018A1 (en) | 1h-pyrrolo[3,2-b]pyridine-3-carboxylic acid amides | |
| US6673811B1 (en) | 1H-pyrrolo [3,2-b] pyridine-3-carboxylic acid amines as GABAA receptor ligands | |
| US6528649B2 (en) | Imidazoloisoquinolines | |
| US20080032975A1 (en) | Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051121 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051121 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090708 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090710 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091013 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091023 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091110 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100105 |